New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its…
CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…
October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc. FX-909, the first small molecule targeting PPARG to be tested…
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses…
October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for…